Abstract
L-Asparaginase (L-ASNase, EC 3.5.1.1) catalyzes the hydrolysis of the non-essential amino acid L-Asn to L-Asp and ammonia and is widely used for the treatment of haematopoetic diseases such as acute lymphoblastic leukaemia (ALL) and lymphomas. Therapeutic forms of L-ASNase come from different biological sources (primarily E. coli and Erwinia chrysanthemi). It is well established that the various preparations have different biochemical pharmacology properties, and different tendency to induce side-effects. This is due to different structural, physicochemical and kinetic properties of L-ASNases from the various biological sources. Understanding these properties of various L-ASNases would allow a better decipherment of their catalytic and therapeutic features, thus enabling more accurate predictions of the behaviour of these enzymes under a variety of therapeutic conditions. In addition, detailed understanding of the catalytic mechanism of L-ASNases might permit the design of new forms of L-ASNases with optimal biochemical properties for clinical applications. In this paper we review the available biochemical and pharmacokinetic information of the therapeutic forms of bacterial L-ASNases, and focus on a detailed description of structure, function and clinical applications of these enzymes.
Keywords: L-Asparaginase, acute lymphoblastic leukemia, catalytic mechanism protein crystallography, protein drug
Related Journals
Related eBooks
Related Articles
-
Gene Therapy for Wiskott-Aldrich Syndrome
Current Gene Therapy The Development of Cytokine Receptor Antagonists as Potential Therapeutic Agents for the Myeloproliferative Disorders
Current Pharmaceutical Design Structural and Functional Role of Gly281 in L-asparaginase from Erwinia carotovora
Protein & Peptide Letters Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality
Reviews on Recent Clinical Trials NBS1 Heterozygosity and Cancer Risk
Current Genomics Machine Learning for Childhood Acute Lymphoblastic Leukaemia Gene Expression Data Analysis: A Review
Current Bioinformatics Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Discriminating Ramos and Jurkat Cells with Image Textures from Diffraction Imaging Flow Cytometry Based on a Support Vector Machine
Current Bioinformatics Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
Anti-Cancer Agents in Medicinal Chemistry Synthesis of a Tyr-Tyr Dipeptide Library and Evaluation Against Tumor Cells
Medicinal Chemistry The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Evaluation of Polygonum bistorta for Anticancer Potential Using Selected Cancer Cell Lines
Medicinal Chemistry Proteomics in Acute Myelogenous Leukaemia (AML): Methodological Strategies and Identification of Protein Targets for Novel Antileukaemic Therapy
Current Drug Targets Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics
Current Pharmaceutical Design Effects of Bioactive Compounds from Carrots (Daucus carota L.), Polyacetylenes, Beta-Carotene and Lutein on Human Lymphoid Leukaemia Cells
Anti-Cancer Agents in Medicinal Chemistry The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Current Cancer Drug Targets The Role of IRF1 and IRF2 Transcription Factors in Leukaemogenesis
Current Gene Therapy